NCT02698735View on ClinicalTrials.gov

Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Nonsense Mutation Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

February 25, 2016

Primary Completion Date

March 31, 2017

Study Completion Date

June 30, 2017

Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
DRUG

Gentamicin

Gentamicin was either formulated into a 0.1% ointment or solutions for injection were purchased directly from suppliers.

DRUG

Placebo

There are two placebos used in this study. The ointment vehicle (same as used to formulate gentamicin) and vehicle solution for injection.

All Listed Sponsors
lead

University of Southern California

OTHER

NCT02698735 - Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Nonsense Mutation Patients | Biotech Hunter | Biotech Hunter